Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Autor: Pastrana DV; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA pastrand@mail.nih.gov., Peretti A; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA., Welch NL; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA., Borgogna C; Novara Medical School, Novara, Italy., Olivero C; Novara Medical School, Novara, Italy., Badolato R; University of Brescia, Brescia, Italy., Notarangelo LD; University of Brescia, Brescia, Italy., Gariglio M; Novara Medical School, Novara, Italy., FitzGerald PC; NCI Genome Analysis Unit, NCI, Bethesda, Maryland, USA., McIntosh CE; NCI Genome Analysis Unit, NCI, Bethesda, Maryland, USA., Reeves J; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA., Starrett GJ; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA., Bliskovsky V; Cancer Genetics Branch, NCI, Bethesda, Maryland, USA., Velez D; Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, Maryland, USA., Brownell I; National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Yarchoan R; HIV and AIDS Malignancy Branch, NCI, Bethesda, Maryland, USA., Wyvill KM; HIV and AIDS Malignancy Branch, NCI, Bethesda, Maryland, USA., Uldrick TS; HIV and AIDS Malignancy Branch, NCI, Bethesda, Maryland, USA., Maldarelli F; Host Virus Interaction Branch, NCI, Bethesda, Maryland, USA., Lisco A; Laboratory of Immunoregulation, NIAID, Bethesda, Maryland, USA., Sereti I; Laboratory of Immunoregulation, NIAID, Bethesda, Maryland, USA., Gonzalez CM; Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA.; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA., Androphy EJ; Stark Neurosciences Research Institute, Indiana University, Indianapolis, Indiana, USA., McBride AA; DNA Tumor Virus Section, NIAID, Bethesda, Maryland, USA., Van Doorslaer K; School of Animal and Comparative Biomedical Sciences, Department of Immunobiology, Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.; School of Animal and Comparative Biomedical Sciences, Department of Immunobiology, Genetics Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.; Bio5 Institute, University of Arizona, Tucson, Arizona, USA.; University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA., Garcia F; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Dvoretzky I; Yale University, New Haven, Connecticut, USA., Liu JS; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Han J; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Murphy PM; Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, Maryland, USA., McDermott DH; Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, Maryland, USA., Buck CB; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA.
Jazyk: angličtina
Zdroj: MSphere [mSphere] 2018 Dec 12; Vol. 3 (6). Date of Electronic Publication: 2018 Dec 12.
DOI: 10.1128/mSphereDirect.00645-18
Abstrakt: Several immunodeficiencies are associated with high susceptibility to persistent and progressive human papillomavirus (HPV) infection leading to a wide range of cutaneous and mucosal lesions. However, the HPV types most commonly associated with such clinical manifestations in these patients have not been systematically defined. Here, we used virion enrichment, rolling circle amplification, and deep sequencing to identify circular DNA viruses present in skin swabs and/or wart biopsy samples from 48 patients with rare genetic immunodeficiencies, including patients with warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome, or epidermodysplasia verruciformis (EV). Their profiles were compared with the profiles of swabs from 14 healthy adults and warts from 6 immunologically normal children. Individual patients were typically infected with multiple HPV types; up to 26 different types were isolated from a single patient (multiple anatomical sites, one time point). Among these, we identified the complete genomes of 83 previously unknown HPV types and 35 incomplete genomes representing possible additional new types. HPV types in the genus Gammapapillomavirus were common in WHIM patients, whereas EV patients mainly shed HPVs from the genus Betapapillomavirus. Preliminary evidence based on three WHIM patients treated with plerixafor, a leukocyte mobilizing agent, suggest that longer-term therapy may correlate with decreased HPV diversity and increased predominance of HPV types associated with childhood skin warts. IMPORTANCE Although some members of the viral family Papillomaviridae cause benign skin warts (papillomas), many human papillomavirus (HPV) infections are not associated with visible symptoms. For example, most healthy adults chronically shed Gammapapillomavirus ( Gamma ) virions from apparently healthy skin surfaces. To further explore the diversity of papillomaviruses, we performed viromic surveys on immunodeficient individuals suffering from florid skin warts. Our results nearly double the number of known Gamma HPV types and suggest that WHIM syndrome patients are uniquely susceptible to Gamma HPV-associated skin warts. Preliminary results suggest that treatment with the drug plerixafor may promote resolution of the unusual Gamma HPV skin warts observed in WHIM patients.
Databáze: MEDLINE